2 files

A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-In-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma

posted on 11.01.2022, 12:48 by Adis Journals on behalf of, Dominic Brittain, Peter D’Andrea, Emilie Gruen, Motoi Hosoe, Devendra JainDevendra Jain, Juergen Jauernig, Abhijit Pethe, Emil Scosyrev, Ana-Maria Tanase, Hanns-Christian Tillman

Article full text

The above talking head video represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

© The authors, CC-BY-NC 2022.